Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on X:
“For metastatic HR positive breast cancer patients, do you do CGP? At baseline or on progression? Only selected mutations or a comprehensive panel? What’s your current clinical practice? Do vote and opine.
- Yes, CGP at baseline
- CGP only atthe second line
- Occasionally
- Esr1 and PIK3CA only.”
More posts featuring Amol Akhade.